Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-1501 in IgA nephropathy
2021-004795-34Phase 2Terminated
- Sponsor
- Eledon Pharmaceuticals, Inc
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegoprubart in IgA nephropathy (IgAN), sponsored by Eledon Pharmaceuticals, Inc. Primary endpoint: Change from baseline in 24-hour urine protein-to-creatinine ratio at 24 weeks. Started Feb 2022; status: terminated.
02
Drugs
tegoprubart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2021-004795-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004795-34.